Cargando…

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review

BACKGROUND: Both intravenous and subcutaneous human immune globin G (IgG) replacement (IVIG and SCIG, respectively) reduce severe infection and increase serum IgG levels in primary immune deficiency disorder (PIDD) patients who require replacement. SCIG can be administered either with the aid of an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Graham, Kalicinsky, Chrystyna, Warrington, Richard, Miguel, Marianne, Reyes, Jeannette, Rubin, Tamar S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218483/ https://www.ncbi.nlm.nih.gov/pubmed/32426003 http://dx.doi.org/10.1186/s13223-020-00431-3

Ejemplares similares

Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor
por: McKibbin, Lundy, et al.
Publicado: (2019)

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
por: Bienvenu, Boris, et al.
Publicado: (2018)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Is response to IVIG in Chronic Idiopathic Urticaria related to presense of autoantibodies?
por: Rosenfield, Lana, et al.
Publicado: (2014)

A retrospective comparison of false negative skin test rates in penicillin allergy, using pencilloyl-poly-lysine and minor determinants or Penicillin G, followed by open challenge
por: Rosenfield, Lana, et al.
Publicado: (2015)

Diagnosing penicillin allergy in the absence of minor determinant mixture
por: Rosenfield, Lana, et al.
Publicado: (2014)

Adult-onset IgE-mediated food allergy at a Winnipeg allergy clinic: a case series
por: Walter, Graham, et al.
Publicado: (2020)

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, A, et al.
Publicado: (2013)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, Adriana, et al.
Publicado: (2012)

Assessment of epicutaneous testing of a monovalent Influenza A (H1N1) 2009 vaccine in egg allergic patients
por: Pitt, Tracy, et al.
Publicado: (2011)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

Development of a Population-Based Newborn Screening Method for Severe Combined Immunodeficiency in Manitoba, Canada
por: Thompson, J. Robert, et al.
Publicado: (2018)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Resolution of antibody in autoimmune urticaria
por: Kalicinsky, Chrystyna, et al.
Publicado: (2011)

Bloodworm induced Anaphylaxis
por: Ho, Peter, et al.
Publicado: (2014)

Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
por: Ho, Peter, et al.
Publicado: (2014)

A novel combination of an IgE mediated adult onset food allergy and a suspected mast cell activation syndrome presenting as anaphylaxis
por: Barber, Colin, et al.
Publicado: (2016)

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
por: Cowan, Juthaporn, et al.
Publicado: (2020)

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)

Comparing wheat flour and commercial wheat extract skin prick testing in Wheat Dependent Exercise Induced Anaphylaxis
por: Rosenfield, Lana A, et al.
Publicado: (2010)

Resolution of wheat-dependent exercise induced anaphylaxis-case report
por: Rosenfield, Lana A, et al.
Publicado: (2010)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Review of icatibant use in the Winnipeg Regional Health Authority
por: Cai, George, et al.
Publicado: (2020)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins
por: Leidenmühler, Peter, et al.
Publicado: (2023)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Prolonged elevation of serum tryptase resulting from intraoperative anaphylaxis to methylene blue
por: Oomah, Sacha, et al.
Publicado: (2010)

Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema
por: Kovaltchouk, Uliana, et al.
Publicado: (2021)

Manitoba
Publicado: (1896)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations
por: Wasserman, Richard L.
Publicado: (2008)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Manitoba the Best
Publicado: (1894)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes
por: Mallick, Rajiv, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3vlofddo544ui9peknnln01b7m